<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996111</url>
  </required_header>
  <id_info>
    <org_study_id>AIPF003</org_study_id>
    <nct_id>NCT01996111</nct_id>
  </id_info>
  <brief_title>Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis</brief_title>
  <acronym>dHACM</acronym>
  <official_title>A Prospective, Randomized, Controlled, Blinded, Comparative Study of Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, controlled, randomized, blinded and comparative, single-center&#xD;
      clinical trial comparing the improvement of patients with recalcitrant plantar fasciitis&#xD;
      symptoms that have received standard of care versus treatment with differing amounts of&#xD;
      injectable dehydrated human amnion/chorion membrane micrografts(dHACM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in Regulatory Status&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of inflammation as measured by AOFAS Hindfoot scores</measure>
    <time_frame>8 Weeks</time_frame>
    <description>The primary objective of this study is to compare the efficacy of the different treatment amounts in reduction of inflammation as measured by AOFAS Hindfoot scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return to normal activities more quickly than with standard of care</measure>
    <time_frame>8 Weeks</time_frame>
    <description>The secondary objective is to demonstrate that patients treated with micronized dHACM injectable will return to normal activities more quickly than with standard of care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by 0-10 Numeric Rating Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient pain scores will be assessed between all groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life as measured by SF-36</measure>
    <time_frame>8 weeks</time_frame>
    <description>SF-36 scores between all groups before and after treatment over a period of eight weeks. Physical Component Score (PCS) and Mental Component Score (MCS) will be evaluation at 8 weeks and compared to baseline</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Plantar Fasciitis</condition>
  <arm_group>
    <arm_group_label>• Group 2:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Group 3:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Group 4:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>• Injection of 1.0 cc of 0.9% Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection of 1.0 cc of 0.9% Saline</intervention_name>
    <description>Injection of 1.0 cc of 0.9% Saline into affected area</description>
    <arm_group_label>• Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension</intervention_name>
    <description>Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area</description>
    <arm_group_label>• Group 2:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension</intervention_name>
    <description>Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area</description>
    <arm_group_label>• Group 3:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension</intervention_name>
    <description>Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area</description>
    <arm_group_label>• Group 4:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years old.&#xD;
&#xD;
          2. Both male and female patients will be selected.&#xD;
&#xD;
          3. Plantar fasciitis has been treated with conservative usual care for at least 8 weeks,&#xD;
             including at least three of the following modalities&#xD;
&#xD;
               -  Rest, Ice, Compression, Elevation (RICE)&#xD;
&#xD;
               -  Corticosteroid injection&#xD;
&#xD;
               -  Stretching exercises&#xD;
&#xD;
               -  Non-steroidal Anti-Inflammatory Drugs (NSAIDs)&#xD;
&#xD;
               -  Orthotics&#xD;
&#xD;
          4. Females of childbearing potential must be willing to use acceptable methods of&#xD;
             contraception (birth control pills, barriers, or abstinence).&#xD;
&#xD;
          5. Patient understands and is willing to participate in the clinical study and can comply&#xD;
             with weekly visits and the follow-up regimen.&#xD;
&#xD;
          6. Patient has read and signed the IRB/IEC approved Informed Consent Form before&#xD;
             screening procedures are undertaken.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Prior surgery at the site.&#xD;
&#xD;
          2. Site that exhibits clinical signs and symptoms of infection.&#xD;
&#xD;
          3. History of chronic plantar fasciitis of more than twelve months.&#xD;
&#xD;
          4. Evidence of significant neurological disease of the feet.&#xD;
&#xD;
          5. Non-ambulatory patients.&#xD;
&#xD;
          6. The presence of comorbidities that can be confused with or can exacerbate the&#xD;
             condition including:&#xD;
&#xD;
               -  Calcaneal stress fracture&#xD;
&#xD;
               -  Nerve entrapment syndrome (Baxter's Nerve Entrapment or Tarsal Tunnel Syndrome)&#xD;
&#xD;
               -  Plantar fascial rupture&#xD;
&#xD;
               -  Systemic disorders associated with enthesiopathy (such as Gout, Reiter's&#xD;
                  syndrome, rheumatoid arthritis, etc.)&#xD;
&#xD;
               -  Achilles tendonitis&#xD;
&#xD;
               -  Fat pad atrophy&#xD;
&#xD;
               -  Fibromyalgia&#xD;
&#xD;
               -  Diabetics with neuropathy&#xD;
&#xD;
          7. Patients with a history of more than two weeks treatment with immuno-suppressants&#xD;
             (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to&#xD;
             initial screening, or who receive such medications during the screening period, or who&#xD;
             are anticipated to require such medications during the course of the study.&#xD;
&#xD;
          8. Patients on any investigational drug(s) or therapeutic device(s) within 30 days&#xD;
             preceding screening.&#xD;
&#xD;
          9. History of radiation therapy at the site.&#xD;
&#xD;
         10. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.&#xD;
&#xD;
         11. Study foot has been previously treated with tissue engineered materials within the&#xD;
             last 30 days.&#xD;
&#xD;
         12. Patients who are unable to understand the aims and objectives of the trial.&#xD;
&#xD;
         13. Presence of any condition(s) which seriously compromises the subject's ability to&#xD;
             complete this study, or has a known history of poor adherence with medical treatment.&#xD;
&#xD;
         14. Pregnant or breast feeding. No pregnancy within the past 6 months.&#xD;
&#xD;
         15. Allergy to Gentamicin and/or Streptomycin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Zelen, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professional Education and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Professional Education and Research Institute</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plantar fasciitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

